Project Grant R43EY036753
Award Date
9/30/24
Completion Date
8/31/25
Dollars Obligated
$361K
Federal Agency
National Eye Institute
Awardee
Human Cell Co (F4N9XZWABV33)
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This $185,000 Project Grant award from the National Eye Institute (NEI) under CFDA 93.867 (Vision Research) supports research to discover novel disease-modifying therapies for the prevention and treatment of glaucoma. The primary awardee, the University of North Texas Health Science Center at Fort Worth, will employ computational pharmacology approaches to identify small molecule inhibitors that can interfere with the GREM1-BMP protein-protein interaction, a key pathogenic mechanism contributing...
This Project Grant award of $526,841 from the National Eye Institute (CFDA 93.867 - Vision Research) will support research at Vanderbilt University Medical Center (VUMC) to investigate the role of cGMP signaling in glaucomatous neurodegeneration. The goal is to probe the mechanisms of retinal ganglion cell (RGC) degeneration in glaucoma, a leading cause of irreversible blindness, in order to identify novel therapeutic targets to protect and potentially restore vision. The research will focus...
The National Eye Institute (NEI), through its Vision Research federal grant program (CFDA 93.867), awarded a $679,159 Project Grant to The Schepens Eye Research Institute, Inc. in Boston, Massachusetts. The grant, awarded on May 1, 2025, supports research aimed at understanding how aging and elevated intraocular pressure (IOP) contribute to the development of glaucoma and impact retinal ganglion cells (RGCs). The research project will investigate the transcriptomic changes in RGCs due to aging...
This Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) provides $1,066,178 to Tavo Biotherapeutics, Inc. (operating as Oculo Therapy LLC) to support late-stage preclinical development and GMP production of a novel extended-release intraocular pressure (IOP)-lowering formulation for the treatment of glaucoma. The funding will enable critical IND-enabling studies for this first-in-class drug candidate using the FDA-approved drug pregabalin as...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research to enhance stem cell restoration of intraocular pressure (IOP) homeostasis in glaucoma through senolytic treatments. The $234,000 award to Oregon Health & Science University aims to use senolytics and senoreverters to restore TM cell IOP homeostatic function in glaucomatous tissue, with or without stem cell transplantation. This research has the...
The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $730,000 Project Grant (CFDA 93.867 - Vision Research) to Human Cell Co, a for-profit biotech firm, to develop an optimized nerve growth factor (NGF) therapy for the treatment of dry eye disease (DED). The funding will support preclinical studies to evaluate the efficacy and mechanism of action of the company's proprietary NGF mutein (HC201) in improving tear film production and corneal...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), supports research to investigate the role of myeloid cells in axon damage and degeneration associated with glaucoma. The research aims to determine whether NAD+-boosting interventions, which have shown promise in promoting axon protection, work through an anti-inflammatory mechanism by inhibiting myeloid cell recruitment. The award provides $423,767.00 over a 2-year period...
This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), supports research to investigate the role of neural activity in improving retinal ganglion cell (RGC) replacement therapies for glaucoma. The $132,597 award to The Schepens Eye Research Institute, Inc. aims to: 1) characterize retinal remodeling following RGC inactivation, and 2) determine if inhibiting host neural activity can enhance the structural and functional integration...
This $460,625 Project Grant was awarded by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) to Yale University. The grant will fund research to investigate the cellular and synaptic mechanisms underlying changes in retinal ganglion cell (RGC) activity following optic nerve injuries in mouse models of glaucoma. Specifically, the project aims to (1) determine the underlying mechanisms for altered RGC activity after increased intraocular pressure or...
The National Eye Institute (NEI) awarded a $568,122 Project Grant under the Vision Research program (CFDA 93.867) to Baylor College of Medicine to conduct research on the role of vascular ligands and neurovascular dysfunction in glaucoma. The project aims to systematically identify endothelial cell-specific ligands that can modulate retinal ganglion cell function and survival in glaucoma, with the goal of developing novel neuroprotective therapies. The award period runs from July 1, 2025 to...